Stelzer Laurie 4
4 · MBX Biosciences, Inc. · Filed Jan 22, 2026
Research Summary
AI-generated summary of this filing
MBX Director Laurie Stelzer Receives 32,000-Share Award
What Happened
Laurie Stelzer, a director of MBX Biosciences (MBX), received a derivative equity award for 32,000 shares on January 20, 2026. The reported acquisition price is $0.00, so no cash was paid at grant. This is a compensation/award grant (not a purchase or sale) and does not represent an immediate open-market buy or sell.
Key Details
- Transaction date: 2026-01-20; filing date: 2026-01-22 (filed within the normal 2‑business‑day window).
- Shares granted: 32,000 derivative shares; reported acquisition price: $0.00.
- Shares owned after transaction: not specified in the provided excerpt.
- Vesting note (from filing): One-third of the shares underlying this option will vest on Jan 20, 2027 (one-year anniversary); the remainder vests monthly over the following two years, subject to continued service.
- Transaction type code: A (award/grant); this is a derivative grant rather than an open‑market purchase.
Context
Derivative awards like this typically represent stock options, restricted stock units (RSUs), or similar awards that vest over time; until vested (and any required exercise steps completed, if applicable), the shares are generally not marketable. Grants are common as director or employee compensation and are informational rather than a direct bullish/bearish trade signal.
Insider Transaction Report
- Award
Stock option (right to buy)
[F1]2026-01-20+32,000→ 32,000 totalExercise: $43.14Exp: 2036-01-20→ Common Stock (32,000 underlying)
Footnotes (1)
- [F1]One-third of the shares underlying this option will vest and become exercisable on January 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.